City of Hope

University of California

Paul J Yazaki

John E Shively

Anna M Wu

Yuman Fong

Andrew A Raubitschek

Mark A Sherman

Jonathan Delong

Jack Shively

Michael Bouvet

Stephen J Forman

Markus Kalkum

Karine Bagramyan

Saul J Priceman

Susanta Kumar Hui

John P Murad

David Colcher

Anna Kozlowska

Hee Jun Lee

John (Jack) E Shively

Srideshikan Sargur Madabushi

Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described.

TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors

Disclosed is a tumor-specific antibody and fluorophore conjugate for detecting, localizing and imaging of various tumors. Also disclosed are methods for detecting, localizing and imaging a solid tumor before or during a tumor resection surgery using the antibody-fluorophore conjugate.

NIR-conjugated tumor-specific antibodies and uses thereof

Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.

Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia

Provided herein, inter alia, are single chain antibody binding domains (VHHs) for use in conjunction with the Assay with a Large Immuno-sorbent Surface Area (ALISSA). Engineered and affinity matured VHHs are used as affinity reagents in the ALISSA resulting in an exceptionally sensitive and precise method for the detection of toxins at miniscule concentrations. Thus, provided herein are methods as well as reagents that can be used to detect the presence of botulinum neurotoxins in quantities well below 1 pg/mL which corresponds to a lethal concentration under presumed equal distribution throughout the human body.

Single chain antibody domains for detection of anti-botulinum neurotoxin domains and methods of their use

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

Humanized anti-CEA T84.66 antibody and uses thereof

Growing community of inventors

Glendale, CA, United States of America

Paul J Yazaki